John Mckune
First SEC filing: Oct. 19, 2023 · Latest: Oct. 19, 2023
Insider at
Insider transactions
Price change vs current quote, split-adjusted for corporate actions since the filing — not benchmarked, not annualized, not size-weighted
| Date | Ticker | Code | Shares | Price | Value | Owned after | Δ own | A/D | vs now |
|---|---|---|---|---|---|---|---|---|---|
| March 1, 2024 | LUNG | A | 28,800 | · | · | 76,210 Direct | +60.75% | Acquired | (price as of 2026-10-02) |
| March 1, 2024 | LUNG | A | 14,400 | · | · | 14,400 Direct | · | Acquired | (price as of 2026-10-02) |
| March 1, 2024 | LUNG | S | 155 | $9.06 | $1,404 | 48,333 Direct | -0.32% | Disposed | -79.8% (price as of 2026-10-02) |
| March 1, 2024 | LUNG | S | 254 | $9.06 | $2,301 | 48,079 Direct | -0.53% | Disposed | -79.8% (price as of 2026-10-02) |
| March 1, 2024 | LUNG | S | 669 | $9.06 | $6,061 | 47,410 Direct | -1.39% | Disposed | -79.8% (price as of 2026-10-02) |
| March 1, 2024 | LUNG | A | 14,400 | · | · | 61,810 Direct | +30.37% | Acquired | (price as of 2026-10-02) |
| March 1, 2024 | LUNG | A | 28,800 | · | · | 28,800 Direct | · | Acquired | (price as of 2026-10-02) |
| Dec. 1, 2023 | LUNG | A | 7,233 | · | · | 47,647 Direct | +17.90% | Acquired | (price as of 2026-10-02) |
| Dec. 1, 2023 | LUNG | S | 585 | $10.34 | $6,049 | 40,414 Direct | -1.43% | Disposed | -82.3% (price as of 2026-10-02) |
| Dec. 1, 2023 | LUNG | S | 222 | $10.34 | $2,295 | 40,999 Direct | -0.54% | Disposed | -82.3% (price as of 2026-10-02) |
| Dec. 1, 2023 | LUNG | S | 135 | $10.33 | $1,395 | 41,221 Direct | -0.33% | Disposed | -82.3% (price as of 2026-10-02) |
| Jan. 4, 2016 | KALV | A | 10,000 | · | · | 10,000 Direct | · | Acquired | |
| Nov. 2, 2015 | KALV | A | 50,000 | · | · | 50,000 Direct | · | Acquired |
P = Open-market purchase · S = Sale · A = Grant/award · M = Option exercise · G = Gift · F = Tax withholding
Insider transactions are not a recommendation; sales are often driven by liquidity or tax reasons.
Derivative holdings (Form 4 Table II) Options, RSUs and convertible securities reported on Form 4 Table II.
| Date | Ticker | Security | Underlying | Exercise price | Expiration | Shares | A/D |
|---|---|---|---|---|---|---|---|
| March 1, 2024 | LUNG | Employee Stock Option (right to buy) | Common Stock | $9.30 | Feb. 28, 2034 | 14,400 | Acquired |
| March 1, 2024 | LUNG | Employee Stock Option (right to buy) | Common Stock | $9.30 | Feb. 28, 2034 | 28,800 | Acquired |
| Jan. 4, 2016 | KALV | Stock Option (Right to buy) | Common Stock | $3.33 | Jan. 4, 2026 | 10,000 | Acquired |
| Nov. 2, 2015 | KALV | Stock Option (Right to Buy) | Common Stock | $4.01 | Nov. 2, 2025 | 50,000 | Acquired |
Exercise/conversion price is blank when not applicable (e.g. RSUs).
Initial ownership (Form 3) 5 holdings
Securities held when first becoming an insider, per SEC Form 3.
| Date | Ticker | Security | Shares | Ownership |
|---|---|---|---|---|
| Oct. 19, 2023 | LUNG | Common Stock | 41,356 | Direct |
| Oct. 19, 2023 | LUNG | Employee Stock Option (right to buy) | 30,050 | Direct |
| Oct. 19, 2023 | LUNG | Employee Stock Option (right to buy) | 13,300 | Direct |
| Oct. 19, 2023 | LUNG | Employee Stock Option (right to buy) | 21,500 | Direct |
| Oct. 19, 2023 | LUNG | Employee Stock Option (right to buy) | 17,500 | Direct |
Compensation (DEF 14A)
Matched by name from proxy statements (DEF 14A) — verify against the filing.
CIK 1348911
| Fiscal year | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension change | Other | Total |
|---|---|---|---|---|---|---|---|---|
| 2017 | $198,703 | $151,701 | · | $24,058 | · | · | $141,617 | $516,080 |
Figures from the Summary Compensation Table of the company's proxy statement (DEF 14A). Compensation is not a recommendation.